Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25682128 | 1.00 | EBP (0.39) | EBPSIGMAR1PDK1 | |
| SCHEMBL25041962 | 1.00 | EBP (0.39) | EBPSIGMAR1PDK1 | |
| SCHEMBL25041958 | 1.00 | EBP (0.39) | EBPSIGMAR1PDK1 | |
| SCHEMBL24717719 | 1.00 | EBP (0.39) | EBPSIGMAR1PDK1 | |
| SCHEMBL24717711 | 0.92 | EBP (0.35) | EBPSIGMAR1 | |
| SCHEMBL25041957 | 0.85 | CHRM2 (0.35) | EBPSIGMAR1 | |
| SCHEMBL10873389 | 0.85 | CHRM2 (0.35) | EBPSIGMAR1 | |
| SCHEMBL25041966 | 0.85 | CHRM2 (0.35) | EBPSIGMAR1 | |
| SCHEMBL25042338 | 0.85 | CHRM2 (0.35) | EBPSIGMAR1 | |
| SCHEMBL24718214 | 0.84 | EBP (0.36) | EBPSIGMAR1PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-06-27 | — | — | US | disclosed |
| US-11674139-B2 | Oligonucleotides for treating expanded repeat diseases | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2022106695-A1 | NUCLEIC ACID DUPLEXES | ALPHA ANOMERIC SAS (FR) | 2022-05-27 | — | — | WO | disclosed |
| US-10017763-B2 | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9944926-B2 | Induced exon inclusion in spinal muscle atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-04-05 | — | — | US | disclosed |
| US-20180066259-A1 | MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD | SAREPTA THERAPEUTICS, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9856474-B2 | Deep intronic target for splicing correction on spinal muscular atrophy gene | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9833468-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-7884194-B2 | epidermal growth factor receptors 2 and 3 proteins; antiproliferative; cancer | AVI BIOPHARMA INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100234281-A1 | ANTIBACTERIAL ANTISENSE OLIGONUCLEOTIDE AND METHOD | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2010-09-16 | — | — | US | disclosed |
| US-20100184670-A1 | ANTISENSE COMPOSITIONS AND METHODS FOR MODULATING CONTACT HYPERSENSITIVITY OR CONTACT DERMATITIS | SAREPTA THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100130591-A1 | MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2010-05-27 | — | — | US | disclosed |
| US-20090246221-A1 | IMMUNOMODULATORY AGENTS AND METHODS OF USE | AVI BIOPHARMA, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090131632-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | AVI BIOPHARMA, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | AVI BIOPHARMA, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090105139-A1 | Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease | AVI BIOPHARMA, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090088562-A1 | Oligonucleotide analogs having cationic intersubunit linkages | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2009-04-02 | — | — | US | disclosed |
| US-20080194463-A1 | Conjugating an arginine-rich carrier to a 3' or 5' end; phosphorodiamidate linkages | AVI BIOPHARMA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105139-A1 | Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease | ERBB2, ERBB3, ERBB4 | EBP 2635/4885SIGMAR1 2405/4885PDK1 3172/4885 |
| US-20100234281-A1 | ANTIBACTERIAL ANTISENSE OLIGONUCLEOTIDE AND METHOD | RNGTT, SPOUT1, MRPL21 | EBP 2779/4885SIGMAR1 832/4885PDK1 4759/4885 |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | HTT, UPF1, TARDBP | EBP 3981/4885SIGMAR1 3685/4885PDK1 4787/4885 |
| US-11674139-B2 | Oligonucleotides for treating expanded repeat diseases | HTT, UPF1, TARDBP | EBP 3981/4885SIGMAR1 3685/4885PDK1 4787/4885 |
| US-20100184670-A1 | ANTISENSE COMPOSITIONS AND METHODS FOR MODULATING CONTACT HYPERSENSITIVITY OR CONTACT DERMATITIS | RTCB, DCLRE1B, C5AR1 | EBP 1705/4885SIGMAR1 1044/4885PDK1 4883/4885 |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | EBP 1750/4885SIGMAR1 4482/4885PDK1 2382/4885 |
| US-20080194463-A1 | Conjugating an arginine-rich carrier to a 3' or 5' end; phosphorodiamidate linkages | RNGTT, BPGM, ARGLU1 | EBP 4271/4885SIGMAR1 1514/4885PDK1 4094/4885 |
| US-20090088562-A1 | Oligonucleotide analogs having cationic intersubunit linkages | SLC38A7, SLC43A3, SLC28A3 | EBP 3656/4885SIGMAR1 1599/4885PDK1 4643/4885 |
| US-20100130591-A1 | MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD | RBM17, UPF1, UTRN | EBP 1345/4885SIGMAR1 4535/4885PDK1 3976/4885 |
| US-20090246221-A1 | IMMUNOMODULATORY AGENTS AND METHODS OF USE | RNGTT, CCR10, CXCL10 | EBP 763/4885SIGMAR1 2214/4885PDK1 4373/4885 |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | EBP 556/4885SIGMAR1 3742/4885PDK1 4784/4885 |
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | RNMT, O60361, PAM | EBP 3971/4885SIGMAR1 2441/4885PDK1 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.